［1］Torbicki A，Perrler A，Konstantinide S，et al.Guideline on the diagnosis and rnanagement of acute pulmonary embolism：the Task Force for the Diagnosis and Managernent of Acute Pulmonary Embolisrn of the European Soclety of Cardiology(ESC)［J］.Eur Heart J，2008，29：2276-2315. 

［2］Sam A，Sánchez D，Gómez V，et al.The shock index and the simplified PESI for identificatlon of low-risk patients with acute pulrnonary embolism［J］.Eur Resplr J，2011，37(4)：762-766. 

［3］Wolde M，Sohne M，Quak E，et al.Prognostic value of echocardiographically assessed right ventricular dysfunction in patients with pulmonary ernbolism［J］.Arch Intern Med，2004，164：1685-1689. 

［4］Jirnenez D，Uresandi F，Otero R，et al.Troponin-based risk stratification of patients with acute nonmassive puirnonary embolisrn：systematlc review and metaanalysis［J］.Chest，2009，136：974-982. 

［5］Lankeit M，Friesen D，Aschoff J，et al.Highly sensitive troponin T assay in normotensive patients with acute pulmonary ernbolism［J］.Eur Heart J，2010，31：1836-1844. 

［6］Klok FA，MoS IC，Huisrnan MV.Brain-type natriuretic peptide levels in the prediction of adverse outcome in patients with pulmonary embolisrn：a systernatic review and meta-analysls［J］.Am J Respir Crit Care Med，2008，178：425-430. 

［7］Dellas C，Puls M，Lankeit M，et al.Elevated heart-type fatty acid-binding protein levels on admission predict an adverse outcorne in norrnotensive patients with acutepulmonary ernbolism［J］.J Am Coll Cardiol，2010，55(19)：2150-2157. 

［8］Lankeit M，Kopf T，Della SC，et al.Growth differentiation factor-15 for prognostic assessrnent of patients with acute pulmonary embolism［J］.Am J Respir Crit Care Med，2008，177(9)：1018-1025. 

［9］Mastora I，Remy-Jardin M，Masson P，et al.Severity of acute pulmonary embolism：evaluation of a new spiral CT angiographic score in correlation with echocardiographic data［J］.Eur Radiol，2003，13(l)：29-35. 

［10］Donze J，Le Gal G，Fine MJ，et al.Prospective validation of the Pulmonary Ernbolism Severity Index.A clinical prognostic model for pulmonary ernbolisrn［J］.Thrornb Haemost，2008，100：943-948. 

［11］Jiménez D，Aujesky D，Moores L，et al.Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism［J］.Arch Intern Med，2010，170(15)：1383-1389. 

［12］Qanadli SD，EI Hajiam M，Vieillard-Baron A，et al.New CT index to quantify arterial obstruction in pulmonary embolism：comparison with angiographic index and echocardiography［J］.AJR Am J Roentgenol，2001，176(6)：1415-1420. 

［13］Jaff MR，McMurtry MS，Archer SL，et al.Management of massive and submassive pulmonary ernbolisrn，lliofemoral deep vein thrornbosls，and chronic thromboembolic pulmonary hypertension：a scientific staternent from the Alllerican Heart Association［J］.Circulation，2011，123(16)：1788-1830. 

［14］Goldhaber SZ，Haire WD，Feldstein ML，et al.Alteplase versus heparin in acute pulmonary embolism：randomised trial assessing right-ventricular function and pulmonary perfusion［J］.Lancet，1993，341：507-511. 

［15］Konstantinides S，Geibel A，Heusel G，et al.Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism［J］.N Engl J Med，2002，347：1143-1150. 

［16］Konstantinides S，Geibel A，Olschewski M，et al.Association between thrombolytic treatment and the prognosis of hemodynamically stable patients with major pulmonary embolism：results of a multicenter registry［J］.Circulation，1997，96(3)：882-888. 

［17］Wan S，Quinlan DJ，Agnelli G，et al.Thrombolysis compared with heparin for the initial treatment of pulmonary embolism：a meta-analysis of the randomized controlled trials［J］.Circulation，2004，110(6)：744-749. 

［18］Wang C，Zhai ZG，Yang Y，et al.Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism：a randomized，multicenter，controlled trial［J］.Chest，2010，137(2)：254-262. 

［19］Steering Committee.Single-bolus tenecteplase plus heparin compared with heparin alone for normotensive patients with acute pulmonary embolism who have evidence of right ventricular dysfunction and myocardial injury：rationale and design of the Pulmonary Embolism Thrombolysis (PEITHO) trial［J］.Am Heart J，2012，163(1)：33-38. 

［20］Guyatt GH，Akl EA，Crowther M，et al.Executive summary：Antithrombotic Therapy and Prevention of Thrombosis，9th ed：American College of Chest Physicians Evidence-Based Clinical Practice Guidelines［J］.Chest，2012，141(2 suppl)：7S-47S. 

［21］Perlroth DJ，Sanders GD，Gould MK.Effectiveness and cost-effectiveness of thrornbolysis in submassive pulmonary embolism［J］.Arch Intern Med，2007，167(1)：74-80. 